A-101 Solution

DRUG3 trials

Sponsors

Aclaris Therapeutics, Inc.

Conditions

Seborrheic Keratosis

Phase 3

A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.

CompletedNCT02667236

Aclaris Therapeutics, Inc.Seborrheic Keratosis

Start: 2016-01-31End: 2016-10-31Updated: 2018-02-06

A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis

CompletedNCT02667275

Aclaris Therapeutics, Inc.Seborrheic Keratosis

Start: 2016-01-31End: 2016-10-31Updated: 2018-02-06

An Open-Label Safety Study of A-101 Solution

CompletedNCT02667288

Aclaris Therapeutics, Inc.Seborrheic Keratosis

Start: 2016-01-31End: 2016-10-31Updated: 2018-02-07